2348 — Dawnrays Pharmaceutical (Holdings) Share News
0.000.00%
Last trade - 00:00- HK$1.57bn
- -HK$170.23m
- CNY1.23bn
Brief: Dawnrays Pharmaceutical (Holdings) Final Dividend Of Hk$0.048 Per Share
Brief: Dawnrays Pharmaceutical Reports HY Net Income Attributable Of RMB104.6 MLN
Brief: Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
Brief: Dawnrays Pharmaceutical (Holdings) Appoints Yu Liwei To Act As CEO
Brief: Dawnrays Pharmaceutical (Holdings) Says Wu Weixian Tendered Resignation As CEO
Brief: Dawnrays Pharmaceutical Posts FY Profit Attributable RMB326.0 Mln
Brief: Dawnrays Pharmaceutical (Holdings) Says Disposal Of Interests In A Joint Venture Company
Brief: Dawnrays Pharmaceutical (Holdings) Says HY Revenue Rmb649.9 Million
Brief: Dawnrays Pharmaceutical (Holdings) Says Provision Of Financial Assistance
Brief: Dawnrays Pharmaceutical Posts HY Profit Attributable Of RMB171.7 Million
Brief: Dawnrays Pharmaceutical Says Wu Weixian Has Been Appointed As Chief Executive Officer Of Company
Brief: Dawnrays Pharmaceutical Announces Disposal Of 35% Stake In Su Zhou Xinshen Pharmaceutical Science And Technology Co
Brief: Dawnrays Pharmaceutical Says Unit Entered Into Product Cooperation Agreements To Engage Nanjing Han Xin Pharmaceutical Technology
Brief: Dawnrays Pharmaceutical HY Profit Attributable Rises 28.5%
Brief: Dawnrays Pharmaceutical (Holdings) Says Disposal Of Interest In A Subsidiary
Brief: Dawnrays Pharmaceutical (Holdings) Recommends Final Dividend Of HK$0.05 Per Share
Brief: Dawnrays Pharmaceutical (Holdings) Says Unit To Provide An Unsecured Loan Of RMB84 Mln To AD Pharmaceuticals
Brief: Dawnrays Pharmaceutical (Holdings) Posts HY Profit Attributable Of RMB 129.7 Mln
Brief: Dawnrays Pharmaceutical (Holdings) Says Unit Entered Into Phase II Construction Agreement